Skip to content
Start free

Wockhardt Ltd.

NSE: WOCKPHARMAHealthcareDrug Manufacturers - Specialty & Generic

Last close
₹1,901.10
Day change
−₹21.80 (−1.13%)vs
Market cap
₹32,848 crIndian rupees
Research updated
—0 reports
Follow Wockhardt

Create an account, then follow this company for weekday briefs. You will return to Wockhardt after signing in.

Share this file

About Wockhardt

Wockhardt Ltd. is a prominent pharmaceutical company that engages in the development, manufacture, and distribution of pharmaceutical and biopharmaceutical formulations. Catering to global healthcare needs, it operates in segments such as generic drugs, biotechnology, and new chemical entities (NCEs). Wockhardt's primary focus is on improving patient health through innovative medications in therapeutic areas like cardiology, neurology, and infectious diseases. As a key player in the pharmaceutical industry, the company also emphasizes research-driven initiatives to address unmet medical needs. With facilities that are US FDA approved, Wockhardt exports its products to markets across the United States, Europe, and Asia, significantly contributing to global healthcare solutions while adhering to stringent quality standards and regulatory requirements.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Listing
NSE: WOCKPHARMA
Next results
Employees
2,564
Headquarters
Mumbai, India
ISIN
INE049B01025
Website
wockhardt.com

Public research

Mool has not published research on Wockhardt yet

With Individual or above

What the full research on Wockhardt includes

Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call.

The report and Mool’s call

  • The 12-month rating and target
  • The 3-month view
  • Mool's estimates beside the street's
  • The claims the view rests on, and what would change it

The analyses, among them

  • Business model & financial foundationWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
  • Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
  • Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.

The research model

The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.

See Mool’s call and the full research

Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.

Same sector

All Healthcare companies

  • Sun Pharmaceutical Industries Ltd.

    NSE: SUNPHARMA

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,777.70 last close on 30 Oct 2026 +0.95%

    Research updated

  • Divi's Laboratories Ltd.

    NSE: DIVISLAB

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹9,780.00 last close on 30 Oct 2026 +1.20%

    Research updated

  • Torrent Pharmaceuticals Ltd.

    NSE: TORNTPHARM

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹4,613.40 last close on 30 Oct 2026 +0.73%

    Research updated

  • Lenskart Solutions Limited

    NSE: LENSKART

    Healthcare · Medical Instruments & Supplies

    ₹678.20 last close on 30 Oct 2026 −0.52%

    Research updated

  • Zydus Lifesciences Ltd.

    NSE: ZYDUSLIFE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,245.50 last close on 30 Oct 2026 +5.16%

    Research updated

Prices are the last close on the NSE, 30 Oct 2026.

Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.